Navigation Links
Alleged Zoloft Birth Defects Lawsuits Report from Resource4thePeople: Federal Judge Schedules Important Status Conference
Date:5/17/2013

San Diego, CA (PRWEB) May 17, 2013

http://www.resource4thepeople.com/defectivedrugs/zoloft.html

Resource4thePeople today announced it is providing consumers its latest update about consolidated federal lawsuits* involving allegations that the use of Zoloft or similar anti-depressants classified as selective serotonin reuptake inhibitors (SSRIs) may cause birth defects in infants.

The latest information in the multidistrict litigation is that the judge in the case has scheduled a Mary 31, 2013 Leadership Status Conference to update her on the process of the litigation. The judge already has scheduled bellwether trials to begin in October of 2014.

The multi-district litigation involves hundreds of cases involving similar allegations under the jurisdiction of U.S. District Court Judge Cynthia M. Rufe in the Eastern District of Pennsylvania.

Judge Rufe has ordered “all members of the Plaintiffs’ Steering Committee as well as Defense counsel” to submit a joint proposed agenda before the meeting in the U.S. Courthouse in Philadelphia, Pa.

“Status conferences such as this perform an important function by updating the judge on the progress of the litigation and consumers benefit by being informed about details involving hundreds of cases alleging that the use of Zoloft and other SSRIs during pregnancies may cause birth defects in infants,” said Resource4thePeople.

Resource4thePeople is also informing consumers who may have used Zoloft that even though the court files* in the case show that there are now over 300 cases consolidated in this litigation the judge has not issued any order preventing future cases from being filed.

"A common question we have been receiving from consumers involves the question of how their legal rights may be affected by the progress of this litigation,” said Resource4thePeople.

“Every case is different but we are continuing to offer free consultations to consumers to help provide them the information they need to preserve all of their legal options over allegations involving the use of SSRIs.”

These consultations can provide legal options about whether such families may be eligible to seek compensation for medical costs, pain and suffering and other expenses that may stem from these circumstances.

Each of the plaintiffs in the multidistrict litigation is seeking at least $75,000 in damages, according to the court files. The manufacturers of Zoloft have denied the allegations.

SSRI anti-depressants are the newest class of anti-depressants and are sold under various brand and generic drug names such as Zoloft, Prozac, Paxil, Lexapro and Depakote. The National Institute of Mental Health web site describes these medications as the most popular antidepressants.**

The common allegations in the Zoloft multidistrict litigation* are that women who used Zoloft to treat depression while pregnant were put at increased risk of giving birth to an infant suffering from birth defects such as cleft palate, club foot, spina bifida and heart and abdominal defects, according to the claims in the court files.

Also claimed in these court filings are allegations that some infants may have been born suffering from the life-threatening condition known as pulmonary hypertension in newborns (PPHN).

This condition, according to the Food and Drug Administration web site, occurs when a newborn baby does not adapt to breathing outside the womb.***

The FDA says that newborns with PPHN may require intensive care support including a mechanical ventilator to increase their oxygen level. If severe, PPHN can result in multiple organ damage, including brain damage, and even death.

Resource4thePeople notes that the FDA has given mixed signals about the link between PPHN and SSRI use. In 2006 the agency issued a warning about the dangers of SSRI use and PPHN. Now the FDA says it is unsure.***

Here is the most recent statement by the FDA, released on Dec. 14, 2011:

“The U.S. Food and Drug Administration (FDA) is updating the public on the use of selective serotonin reuptake inhibitor (SSRI) antidepressants by women during pregnancy and the potential risk of a rare heart and lung condition known as persistent pulmonary hypertension of the newborn (PPHN). The initial Public Health Advisory in July 2006 on this potential risk was based on a single published study. Since then, there have been conflicting findings from new studies evaluating this potential risk, making it unclear whether use of SSRIs during pregnancy can cause PPHN.”

Resource4thePeople also is bringing to the attention of SSRI patients new medical research data that raises concerns about whether the anti-depressants may also put patients at increased risk of suffering heart arrhythmia.

These concerns are raised in published reports of a medical research study in the Jan. 29, 2013 British Medical Journal.

According to the study, the SSRIs citalopram (brand name Celexa) and escitalopram (brand name Lexapro) “trigger a disturbance in QT interval (the duration of electrical activity of the heart muscle) heart rhythms.”

The medical research report's lead study author Dr. Roy Perlis and his colleagues “confirmed through analysis a slight but significant QT prolongation with higher doses of citalopram,” saying that “although some QT variation is normal, a longer interval can upset timing of the heartbeat and lead to dizziness, fainting, and depending on severity, sudden death.”

The researchers also reported that citalopram, escitalopram, and amitriptyline were associated with prolongation of corrected QT interval, which is a marker of increased ventricular arrhythmia risk.

The report emphasized that other antidepressants, including some other SSRIs, were not identified as causing significantly associated with prolonged corrected QT intervals.

Sources:
*In Re: Zoloft (Sertraline Hydrochloride) Products Liability Litigation - MDL 2342, United States District Court, Eastern District of Pennsylvania
**http://www.nimh.nih.gov/health/publications/mental-health-medications/complete-index.shtml
***http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm
**** http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm
*****http://www.bmj.com/content/346/bmj.f288

Read the full story at http://www.prweb.com/releases/2013/5/prweb10738814.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mississippi Woman’s Injuries Allegedly Caused by Ethicon Inc.’s Transvaginal Mesh Device; Parker Waichman LLP Files Lawsuit
2. Alleged Bard IVC Filter Failure Lawsuits Update: Resource4thePeople Reports New Cases Continue To Be Filed
3. New York Woman Suffers Injuries Allegedly Due to Boston Scientific’s Transvaginal Mesh Device, Lawsuit Filed by Parker Waichman LLP
4. d'Oliveira & Associates Offers a New “No Win No Fee Promise” to Those Allegedly Injured from the Hair Loss Drug Propecia
5. Alleged DePuy Knee Sleeve Failure Lawsuits Now Being Reviewed by Resource4thePeople Attorneys
6. Vaginal Mesh Lawsuits Filed Against Boston Scientific on Behalf of Three Women Who Allegedly Sustained Severe Bladder Mesh Sling Injuries, Reports Wright & Schulte
7. Skechers Stress Fractures Lawsuit Filed on Behalf of Woman Who Suffered Six Stress Fractures Allegedly from Skechers Shape-Ups Toning Shoes, by Wright & Schulte LLC
8. NuvaRing Lawsuits Move Forward, as Federal Judge Rules that Plaintiffs’ Experts May Testify on “Bursts” of Estrogen Allegedly Delivered by NuvaRing, Wright & Schulte LLC
9. Bladder Mesh Sling Lawsuit Filed by Wright & Schulte on Behalf of an Iowa Woman Who Sustained Serious Injuries Allegedly Due to Defective Vaginal Mesh Implants
10. Mirena Lawsuits: Bernstein Liebhard LLP Disturbed by New Study Finding IUDs Safe for Teens, In Light of Alleged Mirena Complications
11. Skechers Injury Lawsuit Filed on Behalf of a Texas Woman Who Sustained a Number of Serious Injuries Allegedly Due to Design of Skechers Shape-Ups, By Wright & Schulte
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: